Provided by Tiger Trade Technology Pte. Ltd.

Solid Biosciences

9.16
-0.1400-1.51%
Volume:739.98K
Turnover:6.72M
Market Cap:982.18M
PE:-4.90
High:9.28
Open:9.28
Low:8.86
Close:9.30
52wk High:11.45
52wk Low:3.79
Shares:107.23M
Float Shares:64.81M
Volume Ratio:0.94
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8709
EPS(LYR):-1.9922
ROE:-65.50%
ROA:-36.38%
PB:2.63
PE(LYR):-4.60

Loading ...

Solid Biosciences Price Target Maintained With a $19.00/Share by Needham

Dow Jones
·
Mar 20

Solid Biosciences: De-Risking Duchenne Program and Advancing Gene Therapy Pipeline Supports Buy Rating and $19 Target

TIPRANKS
·
Mar 20

Solid Biosciences (SLDB) Gets a Buy from Chardan Capital

TIPRANKS
·
Mar 20

Solid Biosciences files to sell 42.78M shares of common stock for holders

TIPRANKS
·
Mar 20

Solid Biosciences Inc - Prospectus Filed for Resale of up to 1.3 Mln Shares by Selling Stockholder- SEC Filing

THOMSON REUTERS
·
Mar 20

Solid Biosciences Q4 net loss widens on higher R&D costs

Reuters
·
Mar 20

Solid Biosciences reports Q4 EPS (53c), consensus (52c)

TIPRANKS
·
Mar 20

Solid Biosciences Q4 EPS $(0.53) Misses $(0.50) Estimate

Benzinga Earnings
·
Mar 20

Solid Biosciences Q4 Net Income USD -49.8 Million

THOMSON REUTERS
·
Mar 20

Press Release: Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Dow Jones
·
Mar 20

Solid Biosciences FY2025 net loss widens 39.8% to USD 174.33 million

Reuters
·
Mar 20

U.S. Earnings Preview: After Market Close March 18

Dow Jones
·
Mar 19

Solid Biosciences Is Maintained at Outperform by Wedbush

Dow Jones
·
Mar 12

Solid Biosciences price target raised to $17 from $14 at Wedbush

TIPRANKS
·
Mar 12

Solid Biosciences Publishes Updated Corporate Presentation Online

Reuters
·
Mar 12

Chardan Capital Issues a Buy Rating on Solid Biosciences (SLDB)

TIPRANKS
·
Mar 12

Solid Biosciences: Strengthened Dystrophin Data and Emerging Cardiac Benefits Support Buy Rating on SGT-003

TIPRANKS
·
Mar 12

Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned

Benzinga_recent_news
·
Mar 12

Solid Biosciences says interim results reinforce confidence in SGT-003 potential

TIPRANKS
·
Mar 12

Solid Biosciences reports 40 patients dosed in SGT-003 trial with 60% mean microdystrophin expression at day 90

Reuters
·
Mar 12